Fig. 2

Quantification of neutralizing antibodies by treatment regimen before and after a third dose of mRNA-based SARS-CoV-2 vaccine for variants Wild type (A) and B.1.1.529 (Omicron) (B). The dots show the quantitative estimations of neutralizing antibodies abundance of the patients' baseline and follow-up samples. Dot colors indicate the patients' rheumatic condition. Horizontal dotted lines display the threshold for no detection of antibody (ND) and positivity. SLE Systemic Lupus Erythematosus, RA Rheumatoid Arthritis, B27-AS HLA-B27 positive Ankylosing Spondylitis, PSA Psoriatic Arthritis, GCA Giant Cell Arteritis, GCs Glucocorticoids; JAKi JAK inhibitors, nABs neutralizing antibodies